公开(公告)号：US20250002479A1

公开(公告)日：2025-01-02

申请号：US18826887

申请日：2024-09-06

Applicant: Novartis AG

Inventor： Simone BONAZZI ,  Jennifer Stroka COBB ,  Natalie Alysia DALES ,  Matthew James HESSE ,  Rama JAIN ,  John Ryan KERRIGAN ,  Hasnain Ahmed MALIK ,  James R. MANNING ,  Pamela YF TING

IPC: C07D403/14 ,  A61P7/00 ,  C07D405/14 ,  C07D417/14

Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

公开(公告)号：US20210079015A1

公开(公告)日：2021-03-18

申请号：US16764525

申请日：2018-11-16

Applicant: Novartis AG

Inventor： Jiping FU ,  Mika LINDVALL ,  James R. MANNING ,  Glenn MCENROE

IPC: C07D498/04

Abstract: The invention provides compounds of Formula (I) n R3b Z W Q R3a H Y N R1 R4 R2 O (I) as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20180051015A1

公开(公告)日：2018-02-22

申请号：US15499824

申请日：2017-04-27

Applicant: NOVARTIS AG

Inventor： Thomas Raymond CAFERRO ,  Zhuoliang CHEN ,  Young Shin CHO ,  Abran Q. COSTALES ,  Julian Roy LEVELL ,  Gang LIU ,  James R. MANNING ,  Martin SENDZIK ,  Cynthia SHAFER ,  Michael David SHULTZ ,  James Clifford SUTTON ,  Yaping WANG ,  Qian ZHAO

IPC: C07D413/14 ,  C07D417/14 ,  C07D413/04 ,  A61K31/506 ,  A61K31/5377

CPC classification number: C07D413/14 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D417/14

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

公开(公告)号：US20180057501A1

公开(公告)日：2018-03-01

申请号：US15686652

申请日：2017-08-25

Applicant: Novartis AG

Inventor： Rama JAIN ,  Dennis Christofer KOESTER ,  James R. MANNING ,  Vanessa MARX ,  Daniel POON ,  James Clifford SUTTON ,  Benjamin R. TAFT ,  Lifeng WAN ,  Aregahegn YIFRU ,  Qian ZHAO

IPC: C07D487/14 ,  C07D498/14 ,  C07D471/14

CPC classification number: C07D487/14 ,  C07D471/14 ,  C07D498/14

Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.

公开(公告)号：US20240158374A1

公开(公告)日：2024-05-16

申请号：US18460428

申请日：2023-09-01

Applicant: Novartis AG

Inventor： Simone BONAZZI ,  Artiom CERNIJENKO ,  Jennifer Stroka COBB ,  Natalie Alysia DALES ,  Janetta DEWHURST ,  Matthew James HESSE ,  Rama JAIN ,  John Ryan KERRIGAN ,  Hasnain Ahmed MALIK ,  James R. MANNING ,  Gary O'BRIEN ,  Andrew W. PATTERSON ,  Noel Marie-France THOMSEN ,  Pamela YF TING

IPC: C07D403/14 ,  A61P7/00 ,  C07D405/14 ,  C07D417/14

CPC classification number: C07D403/14 ,  A61P7/00 ,  C07D405/14 ,  C07D417/14

Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

公开(公告)号：US20250011334A1

公开(公告)日：2025-01-09

申请号：US18743020

申请日：2024-06-13

Applicant: Novartis AG

Inventor： Rama JAIN ,  Dennis Christofer KOESTER ,  James R. MANNING ,  Vanessa MARX ,  Daniel POON ,  James Clifford SUTTON ,  Benjamin R. TAFT ,  Lifeng WAN ,  Aregahegn YIFRU ,  Qian ZHAO

IPC: C07D487/14 ,  A61K31/5025 ,  A61K31/53 ,  A61K31/5365 ,  A61K31/5383 ,  A61K31/551 ,  A61P31/16 ,  C07D471/14 ,  C07D498/14

Abstract: The invention provides compounds of Formula (1): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.

公开(公告)号：US20220363671A1

公开(公告)日：2022-11-17

申请号：US17642292

申请日：2020-09-16

Applicant: NOVARTIS AG

Inventor： Jake AXFORD ,  Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Nicole BUSCHMANN ,  Artiom CERNIJENKO ,  Janetta DEWHURST ,  Aleem FAZAL ,  Matthew James HESSE ,  Lauren HOLDER ,  Viktor HORNAK ,  Hidetomo IMASE ,  Rama JAIN ,  Xianming JIN ,  John Ryan KERRIGAN ,  Julie LACHAL ,  Fupeng MA ,  Hasnain Ahmed MALIK ,  James R. MANNING ,  Daniel MCKAY ,  Robert Joseph MOREAU ,  Pierre NIMSGERN ,  Gary O'BRIEN ,  Anna VULPETTI ,  Ken YAMADA ,  Junping ZHAO

IPC: C07D405/04 ,  A61K31/513 ,  C07D471/04 ,  C07D413/04 ,  C07D401/14

Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.

公开(公告)号：US20200347072A1

公开(公告)日：2020-11-05

申请号：US16933000

申请日：2020-07-20

Applicant: Novartis AG

Inventor： Rama JAIN ,  Dennis Christofer KOESTER ,  James R. MANNING ,  James Clifford SUTTON ,  Benjamin Robert TAFT ,  Lifeng WAN ,  Qian ZHAO

IPC: C07D487/14 ,  C07D471/14 ,  C07D491/22 ,  C07D498/14 ,  A61P31/16 ,  C07D513/14

Abstract: The present invention provides a compound of Formula (I) including pharmaceutically acceptable salts thereof: (I) and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions to treat viral infections.

公开(公告)号：US20190092780A1

公开(公告)日：2019-03-28

申请号：US16083089

申请日：2017-03-07

Applicant: Novartis AG

Inventor： Rama JAIN ,  Dennis Christofer KOESTER ,  James R. MANNING ,  James Clifford SUTTON ,  Benjamin Robert TAFT ,  Lifeng WAN ,  Qian ZHAO

IPC: C07D487/14 ,  C07D471/14 ,  C07D491/22 ,  C07D513/14 ,  C07D498/14 ,  A61P31/16

Abstract: The present invention provides a compound of Formula (I) including pharmaceutically acceptable salts thereof: and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions to treat viral infections.